Dermata Therapeutics (DRMA) to Announce Quarterly Earnings on Tuesday

Dermata Therapeutics (NASDAQ:DRMA) is expected to release its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect the company to announce earnings of ($0.55) per share for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

Dermata Therapeutics (NASDAQ:DRMA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.05.

Dermata Therapeutics Stock Performance

Shares of NASDAQ DRMA opened at $1.12 on Tuesday. The firm has a fifty day moving average of $1.25 and a 200 day moving average of $1.37. The firm has a market cap of $4.50 million, a PE ratio of -0.21 and a beta of 0.66. Dermata Therapeutics has a one year low of $0.95 and a one year high of $6.58.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Dermata Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Dermata Therapeutics presently has a consensus rating of “Hold” and an average target price of $10.00.

Institutional Investors Weigh In On Dermata Therapeutics

A hedge fund recently bought a new position in Dermata Therapeutics stock. Clear Street Group Inc. purchased a new stake in Dermata Therapeutics, Inc. (NASDAQ:DRMA) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 17,000 shares of the company’s stock, valued at approximately $39,000. Clear Street Group Inc. owned 0.60% of Dermata Therapeutics as of its most recent filing with the SEC. 8.67% of the stock is currently owned by hedge funds and other institutional investors.

Dermata Therapeutics Company Profile

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.